OKYO Pharma Limited Ordinary Shares

OKYO Pharma will present Phase 2 clinical data for urcosimod, its lead candidate for neuropathic corneal pain treatment, at the ASCRS Annual Meeting in Washington, DC on April 11, 2026. The company will also hold a Scientific Advisory Board meeting with leading ophthalmology experts to review data and guide the upcoming Phase 2b/3 trial planned f...

OKYO Pharma Limited announced that Chief Development Officer Gary Jacob acquired 30,980 ordinary shares at $1.59 per share. The company is advancing its flagship drug urcosimod, a ChemR23 agonist, following positive Phase 2a data in neuropathic corneal pain patients. OKYO plans to initiate a Phase 2b/3 trial with approximately 150 subjects in the...

OKYO Pharma announced that its abstract for urcosimod, a novel non-opioid eye-drop therapy for neuropathic corneal pain (NCP), has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver. The Phase 2a clinical trial demonstrated clinically meaningful pain reduction and quality-of-life improvements in NCP patients, with potential ...

OKYO Pharma Limited announced a public offering of 10.8 million ordinary shares at $1.85 per share, expected to raise approximately $20 million in gross proceeds (up to $23 million with underwriter option). The company plans to use proceeds for clinical development of its product candidates, including a Phase 2b/3 trial of its flagship drug urcos...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company, announced an underwritten public offering of ordinary shares with Piper Sandler & Co. as the sole book-running manager. The company plans to use net proceeds for clinical development of its neuropathic corneal pain and inflammatory eye disease therapies, including a p...